In the UK, more than one million people 1 are currently waiting to access musculoskeletal treatments, leading to delayed care and prolonged recoveries. Sword Health’s innovative solutions address ...
ARLINGTON, Va., Jan. 24, 2025 (GLOBE NEWSWIRE) -- Privia Health Group, Inc. (Nasdaq: PRVA) today announced that it expects to release financial results for its fourth quarter and full-year periods ...
About amycretin Amycretin is a unimolecular long-acting GLP-1 and amylin receptor agonist under development by Novo Nordisk, to provide an efficacious and convenient treatment for adults with ...
NEW YORK, Jan. 24, 2025 (GLOBE NEWSWIRE) -- SoftSmile, Inc., ClearCorrect Operating, LLC, and Institut Straumann AG announce that they have amicably settled all litigation and legal disputes between ...
The CEO Corner segment is now available here. About Autonomix Medical, Inc.
BNA™ Metrics as Cognitive Biomarkers: Baseline brain activation latencies, as measured through Firefly’s BNA™ technology, were longer in MDD patients compared to controls, but normalized ...
The Board of DXS International plc (the “Company” or “DXSP), the AQSE Growth Market quoted clinical decision support developer and supplier of clinical decision support systems, has received ...
Rav Mlait, CEO of Cannabix stated, “We are very pleased to be building a relationship with AlcoPro to begin preliminary ...
J.P. Morgan and Citigroup are acting as joint book-running managers for the offering.
If approved by the EMA, mavorixafor would be the first drug indicated for patients with WHIM syndrome in Europe, a population estimated to be approximately 1,000 people. Earlier this month X4 ...
HOOPP serves Ontario’s hospital and community-based healthcare sector, with more than 700 participating employers. Its membership includes nurses, medical technicians, food services staff, ...
Positron is committed to expanding the cardiac and oncology PET modality by delivering the best technology and value to imaging specialists and will continue to advance its technology through its ...